# A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Source: https://onco.cc/trials/nct06706076/  
OnCo record `nct06706076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Carboplatin, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by BlossomHill Therapeutics, now recruiting.

## Summary

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations is a phase 1/2 interventional study registered as NCT06706076 by BlossomHill Therapeutics, with 675 participants planned, started 2025-01-09 and due to reach its primary completion in 2029-01-31. Interventions recorded: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06706076
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
- Sponsor: BlossomHill Therapeutics
- Enrolled: 675

## Sources

- ClinicalTrials.gov NCT06706076: https://clinicaltrials.gov/study/NCT06706076

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct06706076.json